Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + oxaliplatin + radiotherapy
- Development stage
- Unknown
- Lead developer
- Ghent University Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
gemcitabine + oxaliplatin + radiotherapy is a combination chemo-radiotherapy regimen evaluated for the treatment of locally advanced, unresectable pancreatic adenocarcinoma and distal cholangiocarcinoma. The protocol, studied by University Hospital, Ghent, involves the administration of gemcitabine (a nucleoside analog that inhibits DNA synthesis and ribonucleotide reductase) and oxaliplatin (a platinum-based agent that forms DNA cross-links) in conjunction with ionizing radiation. This multi-modal approach leverages the radiosensitizing properties of gemcitabine to enhance the efficacy of radiotherapy while providing systemic cytotoxic activity through the GemOx doublet. The regimen was assessed in a Phase 1/2 clinical trial to determine the feasibility and recommended dose of oxaliplatin when combined with fixed-dose gemcitabine and radiotherapy.
- Other names
- GemOx-RTgemcitabine + oxaliplatin + radiation therapy
02
Targets
DNARNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on gemcitabine + oxaliplatin + radiotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + oxaliplatin + radiotherapy.